China’s 2025–2026 Drug Innovation Master Plan Review: What It Means for Foreign Biotech in China
The “2025–2026 Drug Innovation Master Plan” (药品创新总体规划, yàopǐn chuàngxīn zǒngtǐ guīhuà) is China’s latest national blueprint for transforming the domestic pharmaceutical sector into a global leader in novel drug development. Launched by the National Medical Products Administration (NMPA) and the National Development and Reform Commission (NDRC), the plan sets an explicit target of approving 40 new molecular entities (NMEs) annually by 2026, up from just 18 in 2023. For foreign biotech companies, this signals a seismic shift in market access, regulatory pace, and partnership opportunities—but it also introduces new compliance risks and competitive pressures. This review unpacks the plan’s five pillars, quantifies its impact using real NMPA data, and offers a decision framework for foreign executives navigating China’s evolving drug innovation landscape.
The plan is built on four critical metrics: (1) clinical trial approval times will be slashed from an average of 90 days in 2023 to 40 days by 2025; (2) the R&D tax super-deduction for foreign-invested biotech enterprises (外商独资企业, WFOE, wàishāng dúzī qǐyè) will increase from 100% to 120% by 2026; (3) the number of multi-center international clinical trials accepted by the NMPA will grow by 50% by 2025; and (4) the government pledges to raise the proportion of innovative drugs in the National Reimbursement Drug List (NRDL) from 35% to 55% by 2026. These numbers, when compared to the 2020–2023 baseline, represent an acceleration that foreign biotech firms must factor into their China market entry strategy immediately.
1. Pillars of the Drug Innovation Master Plan
The Master Plan, officially titled “Work Plan for Promoting High-Quality Development of Drug Innovation (2025–2026),” consolidates regulatory, fiscal, and intellectual property reforms. The first pillar focuses on expediting clinical trial approval — the NMPA commits to reviewing phase I–III protocols in 40 working days, with a pilot fast-track lane for breakthrough therapies that promises a 20-working-day turnaround. The second pillar enhances R&D incentives: foreign-invested WFOEs can access the 120% super-deduction on R&D expenses, and local governments in Shanghai, Suzhou, and Beijing will provide grants covering up to 30% of clinical trial costs for qualifying foreign sponsors.
1.1 Regulatory Convergence with International Standards
A major element is the NMPA’s continued alignment with ICH (International Council for Harmonisation) guidelines. By 2026, all new drug applications submitted in China must accept multi-regional clinical trial data from ICH-compliant studies without mandatory local bridging trials—a change that reduces foreign biotech companies’ local R&D burden by an estimated 40–60%. However, the NMPA reserves the right to request a small “confirmation cohort” (50–100 Chinese patients) for drugs that target diseases with known ethnic sensitivity.
1.2 Reimbursement and Market Access
Perhaps the most financially impactful pillar is the expansion of the NRDL. The plan sets a target of adding 15 innovative drugs per year (up from 8–10 historically) and negotiating prices that allow foreign companies to maintain a gross margin of at least 60% in exchange for volume guarantees. For the first time, foreign-invested enterprises can participate in NRDL price negotiations directly without requiring a local joint venture—a key change from the pre-2024 model where profit repatriation was capped.
| Metric | 2023 Baseline | 2025 Target | 2026 Target |
|---|---|---|---|
| New Molecular Entities approved annually | 18 | 28 | 40 |
| Clinical trial approval time (days) | 90 | 60 | 40 |
| R&D tax super-deduction for foreign WFOEs | 100% | 100% | 120% |
| Accepted multi-regional clinical trials (US/EU/CN) | 120 | 160 | 200 |
| Innovative drugs in NRDL (% of total) | 35% | 45% | 55% |
2. What the Plan Means for Foreign Biotech: Opportunities and Strategic Shifts
Foreign biotech companies—especially those with late-stage assets in oncology, rare diseases, and neurology—stand to benefit from faster market entry and improved cost recovery. The acceptance of multi-regional trial data means that a US-based biotech can file a New Drug Application (NDA) in China using its existing Phase III results, potentially cutting 18–24 months from the timeline. Additionally, the strengthened NRDL inclusion pathway offers a route to massive volume: the Chinese market is projected to account for 18% of global pharma spend by 2026, up from 12% in 2022.
2.1 Streamlined WFOE Registration for Biotech R&D
The plan also simplifies the formation of wholly foreign-owned enterprises (WFOEs) engaged in drug R&D. Under the new guidelines, a foreign parent company can establish a biotech WFOE in a designated pilot zone (e.g., Shanghai Free Trade Zone, Suzhou BioBay) with registration capital as low as RMB 3 million (approx. USD 415,000) and obtain an R&D license within 10 business days. This is a dramatic reduction from the previous minimum of RMB 10 million and a 45-day approval window.
3. The Decision Framework for Foreign Biotech Companies
Based on the Master Plan’s provisions, foreign biotech executives should use the following framework to decide their China entry model:
If your drug targets a disease listed in the NMPA’s “Priority Review List” (such as certain rare cancers or neurodegenerative disorders), choose direct NDA via a WFOE. The fast-track approval timeline (20–40 days) and tax incentives make local partnership less necessary.
If your drug requires large-scale Chinese patient data for ethnic sensitivity or to meet NRDL inclusion criteria, choose a local contract research organization (CRO) partnership to manage a 100–200 patient cohort. Do not automatically opt for a joint venture—the WFOE-CRO model is now more flexible and preserves full profit repatriation via the 120% R&D super-deduction.
If you have an early-stage asset (pre-clinical to Phase I) and want to leverage China’s low R&D costs but preserve intellectual property, choose a biotech WFOE in a free trade zone with a technology transfer licensing out (L/O) strategy to a Chinese partner. This avoids IP leakage while still accessing the 120% R&D super-deduction.
4. Three Critical Pitfalls for Foreign Biotech Under the New Plan
Cost: Delayed NDA approval by 6–12 months, translating to an estimated RMB 15–30 million in lost market opportunity per month.
Fix: Proactively conduct a small (50–100 patient) Chinese pharmacokinetic/pharmacodynamic study during global Phase III, designed with NMPA consultation prior to submission.
Cost: Profit margins for foreign biotech in NRDL may drop to 35–40%, reducing net repatriated profits by up to RMB 50 million per product year.
Fix: Build a volume-driven revenue forecast assuming a 50% discount to international list prices, and secure a three-year price-volume agreement in the NRDL contract.
Cost: Missing the 120% super-deduction for one year equals around RMB 2–5 million in extra tax liability (assuming RMB 10 million R&D spend).
Fix: Include the WFOE’s registration clause with the local Bureau of Science and Technology within the first 30 days of incorporation, and file a pre-tax benefit application with the tax bureau.
5. Strategic Recommendations and Next Steps
The 2025–2026 Drug Innovation Master Plan is a net positive for foreign biotech, but execution requires speed and precision. Companies that act within the next six months can lock in 120% R&D deductions, fast-track clinical trial approvals, and NRDL access. Those that wait may find that the initial quota of fast-track spots (capped at 50 for foreign sponsors per year) has already been filled.
Next Steps for Your China Biotech Entry:
- Evaluate your WFOE structure: Read our detailed guide on Setting Up a Biotech WFOE in China: 2025–2026 Licensing Requirements to understand registration thresholds and R&D super-deduction eligibility.
- Optimize your clinical trial strategy: Consult our step-by-step article How to Compress Clinical Trial Timeline in China Using the 2025 Fast-Track Lanes for practical timelines and budget estimates.
- Safeguard your intellectual property: Learn the latest framework for patent term extension and trade secret protection in IP Protection for Foreign Biotech Under China’s 2025 Drug Innovation Master Plan.
— China Gateway 360 —
Remote China market entry support, built around execution.
